iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study

被引：5
|
作者：
Lajara, Rosemarie
Heller, Caroline
Pantalone, Kevin M.
Lew, Elisheva
Li, Xuan
Dex, Terry A.
Kilpatrick, Rachel
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-739-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Initiation of iGlarLixi vs. Basal-Bolus Insulin (BB) in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: The SoliComplex Real-World Study
    Pantalone, Kevin M.
    Heller, Caroline
    Lajara, Rosemarie
    Lew, Elisheva
    Li, Xuan
    Dex, Terry A.
    Kilpatrick, Rachel
    [J]. DIABETES, 2022, 71
  • [2] iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study
    Lajara, Rosemarie
    Heller, Caroline
    Pantalone, Kevin M.
    Lew, Elisheva
    Li, Xuan
    Dex, Terry
    Kilpatrick, Catherine Rachel
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (05): : 1249 - 1260
  • [3] iGlarLixi vs. Basal plus Rapid-Acting Insulin in Adults with Type 2 Diabetes Advancing from Basal Insulin Therapy: The SoliSimplify Real-World Study
    McCrimmon, Rory J.
    Cheng, Alice Y.
    Galstyan, Gagik R.
    Djaballah, Khier
    Li, Xuan
    Coudert, Mathieu
    Frias, Juan Pablo
    [J]. DIABETES, 2022, 71
  • [4] Iglarlixi vs basal plus rapid-acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: the SoliSimplify real-world study
    McCrimmon, R. J.
    Cheng, A. Y. Y.
    Galstyan, G.
    Djaballah, K.
    Li, X.
    Coudert, M.
    Frias, J.
    [J]. DIABETOLOGIA, 2022, 65 (SUPPL 1) : S331 - S332
  • [5] iGlarLixi versus basal plus Rapid-Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real-World study
    McCrimmon, Rory J.
    Cheng, Alice Y. Y.
    Galstyan, Gagik
    Djaballah, Khier
    Li, Xuan
    Coudert, Mathieu
    Frias, Juan P.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (01): : 68 - 77
  • [6] iGlarLixi vs. Basal-Bolus (BB) or Premixed Insulin in Older Adult Ethnic Minorities with Type 2 Diabetes (T2D)
    Umpierrez, Guillermo
    Gill, Jasvinder
    Hood, David
    Li, Xuan
    Nunez, Ana
    [J]. DIABETES, 2024, 73
  • [7] REAL-WORLD ECONOMIC OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) TREATED WITH DULAGLUTIDE (DU) VS. BASAL INSULIN (BI) IN THE US: THE DISPEL™ STUDY
    Mody, R.
    Huang, Q.
    Yu, M.
    Zhang, X.
    Wang, L.
    Grabner, M.
    Patel, H.
    [J]. VALUE IN HEALTH, 2019, 22 : S149 - S150
  • [8] Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with IGlarLixi vs. Premix 70/30 in the SoliMix Trial
    Rosenstock, Julio
    Emral, Rifat
    Sauque-Reyna, Leobardo
    Mohan, Viswanathan
    Trescoli, Carlos
    Al Sifri, Saud N.
    Lalic, Nebojsa
    Alvarez, Agustina
    Picard, Pascaline
    Demil, Nacima
    Bonnemaire, Mireille
    McCrimmon, Rory J.
    [J]. DIABETES, 2021, 70
  • [9] Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial Outside Europe
    Fonseca, Vivian
    Rosenstock, Julio
    Cheng, Alice Y.
    Emral, Rifat
    Sauque-Reyna, Leobardo
    Mohan, Viswanathan
    Al Sifri, Saud N.
    Alvarez, Agustina
    Djaballah, Khier
    Picard, Pascaline
    Souhami, Elisabeth
    Mccrimmon, Rory J.
    [J]. DIABETES, 2021, 70
  • [10] Advancing Therapy in Uncontrolled Basal Insulin (BI)-Treated Type 2 Diabetes (T2D): Subanalysis of the SoliMix Trial in Participants in Europe
    Cheng, Alice Y.
    Mccrimmon, Rory J.
    Fonseca, Vivian
    Trescoli, Carlos
    Haluzik, Martin
    Seufert, Jochen
    Alvarez, Agustina
    Souhami, Elisabeth
    Picard, Pascaline
    Bonnemaire, Mireille
    Rosenstock, Julio
    [J]. DIABETES, 2021, 70
12345